A gender-related action of IFNbeta-therapy was found in multiple sclerosis

Journal of Translational Medicine

Anna Maria Berghella¹  Antonio Carolei²  Tiziana Del Beato¹  Patrizia Pellegrini¹  Rocco Totaro²  Ida Contasta¹ 

[1] Consiglio Nazionale delle Ricerche (CNR), Istituto di Farmacologia Traslazionale (IFT), via G Carducci, 32-Rotilio Center, L’Aquila 67100, Italy;Dipartimento di Neurologia dell’Università di L’Aquila, L’Aquila 67100, Italy

关键词: Clinical biomarkers;    Clinical targets;    CD30;    Th cell networks;    Th cytokine networks;    Multiple sclerosis;    Autoimmune diseases;    Gender differences;   

Others  :  828925
DOI  :  10.1186/1479-5876-10-223

 received in 2012-07-03, accepted in 2012-11-05,  发布年份 2012

【 摘 要 】

Background

Understanding how sexual dimorphism affects the physiological and pathological responses of the immune system is of considerable clinical importance and could lead to new approaches in therapy. Sexual dimorphism has already been noted as an important factor in autoimmune diseases: the aim of this study was to establish whether sexual dimorphism in autoimmune diseases is the result of differing pathways being involved in the regulation of T-helper (Th) cell network homeostasis.

Methods

We focused on sexually dimorphic changes in the immune response in multiple sclerosis (MS) patients in order to ascertain how these alterations relate to the pathway regulation of the cytokine homeostasis and the Th cell networks. We studied antigen presenting cell (APC)-dependent T cell activation in groups of healthy subjects, in patients under interferon (IFN) β-therapy and untreated. Cytokines, soluble (s) CD30 and the expanded disability status scale (EDSS) were used as biomarkers for T cell differentiation and neurological deficit.

Results

The data confirm our belief that sexual dimorphism in autoimmune diseases is the result of differing pathways that regulate Th cell network homeostasis: interleukin (IL) 6 pathways in women and IFNγ pathways in men. Given the increased susceptibility of women to MS and the significance of IL6 in the autoimmune process compared to IFNγ, it is logical to assume that IL6 pathways are in some way implicated in the prevalence of autoimmune diseases in women. Indeed, our data indicate that IL6 pathways are also involved in T regulatory (Treg) cell imbalance and an increase in neurological deficit in both men and women groups of MS patients, underlining the autoimmune etiology of multiple sclerosis. In further support of differing cytokine pathways in men and women, we noted that the efficacy of IFNβ-treatment in the re-establishment of Th-network balance and in the delaying of the neurological disability progression is linked to the IL6 pathway in women, but to the IFNγ pathway in men. Lastly, we also identified specific gender biomarkers for the use in therapy.

Conclusions

The identification of gender-specific drugs is of considerable importance in translational medicine and will undoubtedly lead to more appropriate therapeutic strategies and more successful treatment.

【 授权许可】

   
2012 Contasta et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Whitacre CC: Sex differences in autoimmune disease. Nat Immunol 2001, 2:777-780.
• [2]McCarthy M: The “gender gap” in autoimmune disease. Lancet 2000, 356:1088.
• [3]Beageley KW, Gockel CM: Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone. FEMS Immunol Med Microbiol 2003, 38:13-22.
• [4]Gleicher N: Some thoughts on the reproductive autoimmune failure syndrome (RAFS) and TH-1 versus TH-2 immune responses. Am J Reprod Immunol 2002, 48:252-254.
• [5]Yakoo T, Takakuwa K, Ooki I, Kikuchi A, Tamura M, Tanaka K: Alterations of TH1 and TH2 cells by intracellular cytokine detection in patients with unexplained recurrent abortion before and after immunotherapy with the husband’s mononuclear cells. Fertil Steril 2006, 85:1452-1458.
• [6]Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986, 136:2348-2357.
• [7]Mosmann TR, Coffman RL: TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989, 7:145-173.
• [8]Lucey DR, Clerici M, Shearer GM: Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 1996, 9(4):532-562.
• [9]Murphy KM, Reiner SL: The lineage decisions of helper T cells. Nat Rev Immunol 2002, 2:933-944.
• [10]Zhou L, Chong MM, Littman DR: Plasticity of CD4+T cell lineage differentiation. Immunity 2009, 30:646-655.
• [11]Weaver CT, Hatton RD, Mangan PR, Harrington LE: IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007, 25:821-852.
• [12]Schubert LA, Jeffery E, Zhang Y, Ramsdell F, Ziegler SF: Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation. J Biol Chem 2001, 276:37672-37679.
• [13]Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD: The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001, 27:20-21.
• [14]Manel N, Unutmaz D, Littman DR: The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 2008, 9:641-649.
• [15]Volpe E, Servant N, Zollinger R, Bogiatzi SI, Hupe P, Barillot E, Soumelis V: A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol 2008, 9:650-657.
• [16]Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M, Kuchroo VK, Hafler DA: IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 2008, 454:350-352.
• [17]Dardalhon V, Awasthi A, Kwon H, Galileos G, Gao W, Sobel RA, Mitsdoerffer M, Strom TB, Elyaman W, Ho IC, Khoury S, Oukka M, Kuchroo VK: IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(−) effector T cells. Nat Immunol 2008, 9:1347-1355.
• [18]Veldhoen M, Uyttenhove C, van Snick J, Helmby H, Westendorf A, Buer J, Martin B, Wilhelm C, Stockinger B: Transforming growth factor beta ‘reprograms’ the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 2008, 9:1341-1346.
• [19]Greer JM, McCombe PA: Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms. J Neuroimmunol 2011, 234(1–2):7-18.
• [20]Polman CH, Miller DH, McDonald WI, Thompson AJ: Treatment recommendations for interferon-beta in multiple sclerosis. J Neurol Neurosurg Psychiatry 1999, 67:561-564.
• [21]Grigoriadis N: Interferon beta treatment in relapsing-remitting multiple sclerosis. A review. Clin Neurol Neurosurg 2002, 104:251-258.
• [22]Contasta I, Totaro R, Berghella AM, Pellegrini P, Del Beato T, Carolei A, Adorno D: Soluble CD30: a biomarker for evaluating the clinical risk versus benefit of IFNbeta1A treatment in multiple sclerosis patients. Int J Immunopathol Pharmacol 2010, 23(1):213-226.
• [23]Pellegrini P, Totaro R, Contasta I, Berghella AM, Carolei A, Adorno D: CD30 antigen and multiple sclerosis: CD30, an important costimulatory molecule and marker of a regulatory subpopulation of dendritic cells, is involved in the maintenance of the physiological balance between TH1/TH2 immune responses and tolerance. The role of IFNbeta-1a in the treatment of multiple sclerosis. Neuroimmunomodulation 2005, 12(4):220-234.
• [24]Berghella AM, Pellegrini P, Del Beato T, Ciccone F, Contasta I: The potential role of thioredoxin 1 and CD30 systems as multiple pathway targets and biomarkers in tumor therapy. Cancer Immunol Immunother 2011, 60(10):1373-1381.
• [25]Bray D: Reasoning for results. Nature 2001, 412(6850):863.
• [26]Janes KA, Lauffenburger DA: A biological approach to computational models of proteomic networks. Curr Opin Chem Biol 2006, 10(1):73-80.
• [27]Randerson PF: Why do we need multivariate analysis? In Biological Data Analysis. A Pratical Approach. Edited by Fry JC. New York, NY, USA: Oxford University Press; 1993:173.
• [28]Thomson A: The Cytokine Handbook. San Diego, Calif, USA: Academic Press; 1994.
• [29]Banchereau J: Converging and diverging properties of human interleukin-4 and interleukin-10. Behring Inst Mitt 1995, 96:58-77.
• [30]Cua DJ, Kastelein RA: TGF-β, a “double agent” in the immune pathology war. Nat Immunol 2006, 7(6):557-559.
• [31]Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441(7090):235-238.
• [32]Wong MT, Ye JJ, Alonso MN, Landrigan A, Cheung RK, Engleman E, Utz PJ: Regulation of human Th9 differentiation by type I interferons and IL-21. Immunol Cell Biol 2010, 88(6):624-631.
• [33]Pellegrini P, Totaro R, Contasta I, Berghella AM, Russo T, Carolei A, Adorno D: IFNβ1a treatment and reestablishment of Th1 regulation in MS patients: dose effects. Neuropharmacol 2004, 27:258-269.
• [34]Bloemena E, Roos MT, Van-Heijst JL, Vossen JM, Schellekens PT: Whole blood lymphocyte cultures. J Immunol Methods 1989, 122:161-167.
• [35]Cohen SBA, Clayton J, Londei M, Feldmann M: T Cells and cytokines. In Cytokines. 2nd edition. Edited by Rickwood D, Hames BD. New York: Oxford University Press; 1995:179.
• [36]Doyle A, Stein M, Keshavi S, Gordon S: Assays for macrophage activation by cytokines. In Cytokines. 2nd edition. Edited by Rickwood D, Hames BD. New York: Oxford University Press; 1995:269.
• [37]Berghella AM, Pellegrini P, Piancatelli D, Maccarone D, Del Beato T, Giubilei D, Pomidori A, Adorno D, Casciani CU: Progression mechanisms in colon cancer: soluble interleukin-2 (IL-2) receptor, IL-2 plus anti-CD3 proliferative response and tumour stage correlations. Cancer Immunol Immunother 1994, 38(3):160-166.
• [38]Azuaje F, Devaux Y, Wagner DR: Coordinated modular functionality and prognostic potential of a heart failure biomarker-driven interaction network. BMC Syst Biol 2010, 12(4):60.
• [39]Fujita A, Gomes LR, Sato JR, Yamaguchi R, Thomaz CE, Sogayar MC, Miyano S: Multivariate gene expression analysis reveals functional connectivity changes between normal/tumoral prostates. BMC Syst Biol 2008, 2(5):10.
• [40]Janes KA, Lauffenburger DA: A biological approach to computational models of proteomic networks. Curr Opin Chem Biol 2006, 10(1):73-80.
• [41]Gonzalez E, van Liempd S, Conde-Vancells J, Gutierrez-de Juan V, Perez-Cormenzana M, Mayo R, Berisa A, Alonso C, Marquez CA, Barr J, Lu SC, Mato JM, Falcon-Perez JM: Serum UPLC-MS/MS metabolic profiling in an experimental model for acute-liver injury reveals potential biomarkers for hepatotoxicity. Metabolomics 2012, 8:997-1011.
• [42]Janes KA, Yaffe MB: Data driven modelling of signal transduction networks. Nat Rev 2006, 7:820-828.
• [43]Pace L, Pioli C, Doria G: IL-4 modulation of CD4+CD25+ T regulatory cell-mediated suppression. J Immunol 2005, 174(12):7645-7653.
• [44]Kim JM, Rasmussen JP, Rudensky AY: Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 2007, 8:191-197.
• [45]Korn T, Mitsdoerffer M, Croxford AL, Awasthi A, Dardalhon VA, Galileos G, Vollmar P, Stritesky GL, Kaplan MH, Waisman A, Kuchroo VK, Oukka M: IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci USA 2008, 105(47):18460-18465.
• [46]Nowak EC, Weaver CT, Turner H, Begum-Haque S, Becher B, Schreiner B, Coyle AJ, Kasper LH, Noelle RJ: IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med 2009, 206:1653-1660.
• [47]Zhou Y, Sonobe Y, Akahori T, Jin S, Kawanokuchi J, Noda M, Iwakura Y, Mizuno T, Suzumura A: IL-9 promotes Th17 cell migration into the central nervous system via CC chemokine ligand-20 produced by astrocytes. J Immunol 2011, 186(7):4415-4421.
• [48]Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, Sedgwick JD, Cua DJ: Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003, 198:1951-1957.
• [49]Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L: Interleukin-17 production in central nervous system infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008, 172:146-155.